Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tamalee Scott is active.

Publication


Featured researches published by Tamalee Scott.


Journal of Immunology | 2003

Irradiation of Tumor Cells Up-Regulates Fas and Enhances CTL Lytic Activity and CTL Adoptive Immunotherapy

Mala Chakraborty; Scott I. Abrams; Kevin Camphausen; Kebin Liu; Tamalee Scott; C. Norman Coleman; James W. Hodge

CD8+ CTL play important roles against malignancy in both active and passive immunotherapy. Nonetheless, the success of antitumor CTL responses may be improved by additional therapeutic modalities. Radiotherapy, which has a long-standing use in treating neoplastic disease, has been found to induce unique biologic alterations in cancer cells affecting Fas gene expression, which, consequently, may influence the overall lytic efficiency of CTL. Here, in a mouse adenocarcinoma cell model, we examined whether exposure of these tumor cells to sublethal doses of irradiation 1) enhances Fas expression, leading to more efficient CTL killing via Fas-dependent mechanisms in vitro; and 2) improves antitumor activity in vivo by adoptive transfer of these Ag-specific CTL. Treatment of carcinoembryonic Ag-expressing MC38 adenocarcinoma cells with irradiation (20 Gy) in vitro enhanced Fas expression at molecular, phenotypic, and functional levels. Furthermore, irradiation sensitized these targets to Ag-specific CTL killing via the Fas/Fas ligand pathway. We examined the effect of localized irradiation of s.c. growing tumors on the efficiency of CTL adoptive immunotherapy. Irradiation caused up-regulation of Fas by these tumor cells in situ, based on immunohistochemistry. Moreover, localized irradiation of the tumor significantly potentiated tumor rejection by these carcinoembryonic Ag-specific CTL. Overall, these results showed for the first time that 1) regulation of the Fas pathway in tumor cells by irradiation plays an important role in their sensitization to Ag-specific CTL; and 2) a combination regimen of tumor-targeted irradiation and CTL promotes more effective antitumor responses in vivo, which may have implications for the combination of immunotherapy and radiation therapy.


International Journal of Cancer | 2005

Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid

Kevin Camphausen; David Cerna; Tamalee Scott; Mary Sproull; William E. Burgan; Michael A. Cerra; Howard A. Fine; Philip J. Tofilon

Valproic acid (VA) is a well‐tolerated drug used to treat seizure disorders and has recently been shown to inhibit histone deacetylase (HDAC). Because HDAC modulates chromatin structure and gene expression, parameters considered to influence radioresponse, we investigated the effects of VA on the radiosensitivity of human brain tumor cells grown in vitro and in vivo. The human brain tumor cell lines SF539 and U251 were used in our study. Histone hyperacetylation served as an indicator of HDAC inhibition. The effects of VA on tumor cell radiosensitivity in vitro were assessed using a clonogenic survival assay and γH2AX expression was determined as a measure of radiation‐induced DNA double strand breaks. The effect of VA on the in vivo radioresponse of brain tumor cells was evaluated according to tumor growth delay analysis carried out on U251 xenografts. Irradiation at the time of maximum VA‐induced histone hyperacetylation resulted in significant increases in the radiosensitivity of both SF539 and U251 cells. The radiosensitization was accompanied by a prolonged expression of γH2AX. VA administration to mice resulted in a clearly detectable level of histone hyperacetylation in U251 xenografts. Irradiation of U251 tumors in mice treated with VA resulted in an increase in radiation‐induced tumor growth delay. Valproic acid enhanced the radiosensitivity of both SF539 and U251 cell lines in vitro and U251 xenografts in vivo, which correlated with the induction of histone hyperacetylation. Moreover, the VA‐mediated increase in radiation‐induced cell killing seemed to involve the inhibition of DNA DSB repair.


Clinical Cancer Research | 2004

Enhancement of Xenograft Tumor Radiosensitivity by the Histone Deacetylase Inhibitor MS-275 and Correlation with Histone Hyperacetylation

Kevin Camphausen; Tamalee Scott; Mary Sproull; Philip J. Tofilon

Purpose: Histone deacetylase (HDAC) inhibitors are undergoing clinical evaluation in cancer therapy. Because HDAC modulation has been shown to enhance the radiosensitivity of tumor cells in vitro, we investigated the effects of the HDAC inhibitor MS-275 on the radioresponse of DU145 prostate carcinoma xenografts. Experimental Design: As an indicator of HDAC inhibition in vivo, the histone acetylation status in tumor lysates was determined after two, four, and six injections of MS-275 delivered at 12-hour intervals, as well as 24 and 48 hours after the last injection. Tumor growth delay studies were then performed using this DU-145 xenograft model with radiation administered to leg tumors after the fourth dose of MS-275, which corresponded to the time of maximum histone hyperacetylation. Results: An increase in histone hyperacetylation was detected in each tumor after two injections of MS-275 with a maximum hyperacetylation occurring after four to six injections. In tumor growth delay studies, the combination of MS-275 and radiation resulted in a greater than additive inhibition of tumor growth as compared with the individual modalities. As alternative sources for an indicator of drug radiosensitizing activity, histone hyperacetylation was determined in a series of normal tissues, including lymphocytes. Each of the normal tissues also had a maximal histone hyperacetylation after four to six injections of MS-275. Conclusions: These studies show that MS-275 enhances the radiosensitivity of DU145 xenografts and suggest that histone hyperacetylation status can serve as a useful marker for drug radiosensitizing activity.


Cancer Research | 2005

Orthotopic Growth of Human Glioma Cells Quantitatively and Qualitatively Influences Radiation-Induced Changes in Gene Expression

Kevin Camphausen; Benjamin Purow; Mary Sproull; Tamalee Scott; Tomoko Ozawa; Dennis F. Deen; Philip J. Tofilon

The effect of radiation on gene expression has been most frequently studied using tissue culture models. To determine the influence of experimental growth condition on radiation-induced changes in gene expression, microarray analysis was done on two human glioma cell lines (U87 and U251) grown in tissue culture and as s.c. or i.c. xenografts. Compared with tissue culture, the number of genes, whose expression was affected by radiation in both cell lines, was increased in the s.c. xenografts and further increased in the orthotopic tumors. Furthermore, in each growth condition, radiation modulated the expression of a different set of genes. In addition, whereas there were few commonly affected genes after irradiation of U87 and U251 in tissue culture, there were 729 common changes after orthotopic irradiation. These results indicate that the influence of the orthotopic environment on radiation-induced modulation of gene expression in glioma cells was both quantitative and qualitative. Moreover, they suggest that investigations of the functional consequence of radiation-induced gene expression will require accounting for experimental growth conditions.


Journal of Cellular and Molecular Medicine | 2011

Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102

Ian M. Buchanan; Tamalee Scott; Anita Tandle; William E. Burgan; Teresa L. Burgess; Philip J. Tofilon; Kevin Camphausen

The hepatocyte growth factor (HGF)/Met signalling pathway is up‐regulated in many cancers, with downstream mediators playing a role in DNA double strand break repair. Previous studies have shown increased radiosensitization of tumours through modulation of Met signalling by genetic methods. We investigated the effects of the anti‐HGF monoclonal antibody, AMG102, on the response to ionizing radiation in a model of glioblastoma multiforme in vitro and in vivo. Radiosensitivity was evaluated in vitro in the U‐87 MG human glioma cell line. Met activation was measured by Western blot, and the effect on survival following radiation was evaluated by clonogenic assay. Mechanism of cell death was evaluated by apoptosis and mitotic catastrophe assays. DNA damage was quantitated by γH2AX foci and neutral comet assay. Growth kinetics of subcutaneous tumours was used to assess the effects of AMG102 on in vivo tumour radiosensitivity. AMG102 inhibited Met activation after irradiation. An enhancement of radiation cell killing was shown with no toxicity using drug alone. Retention of γH2AX foci at 6 and 24 hrs following the drug/radiation combination indicated an inhibition of DNA repair following radiation, and comet assay confirmed DNA damage persisting over the same duration. At 48 and 72 hrs following radiation, a significant increase of cells undergoing mitotic catastrophe was seen in the drug/radiation treated cells. Growth of subcutaneous tumours was slowed in combination treated mice, with an effect that was greater than additive for each modality individually. Modulation of Met signalling with AMG102 may prove a novel radiation sensitizing strategy. Our data indicate that DNA repair processes downstream of Met are impaired leading to increased cell death through mitotic catastrophe.


Clinical Cancer Research | 2006

Tumor-Directed Radiation and the Immunotoxin SS1P in the Treatment of Mesothelin-Expressing Tumor Xenografts

Raffit Hassan; Juanita Williams-Gould; Seth M. Steinberg; David J. Liewehr; Junko Yokokawa; Kwong Y. Tsang; Robert J. Surawski; Tamalee Scott; Kevin Camphausen

Purpose: Mesothelin is a cell surface protein overexpressed in mesotheliomas and pancreatic and ovarian cancers. The goal of this study was to determine if radiation therapy in combination with the antimesothelin immunotoxin SS1(dsFv)PE38 (SS1P) would result in enhanced antitumor activity against mesothelin-expressing xenografts in nude mice. Experimental Design: Female athymic nude mice bearing s.c. mesothelin-expressing xenografts were treated with SS1P alone, tumor-focused radiation alone, or the combination of the two. Two different regimens of the combination therapy were tested. In the low-dose combination schedule, mice were treated with either 5 Gy radiation alone, 0.2 mg/kg SS1P alone, or the same doses of radiation and SS1P in combination. In the high-dose combination experiments, mice were treated with either 15 Gy radiation alone, 0.3 mg/kg SS1P alone, or the combination of radiation and SS1P. Results: In the low-dose radiation and SS1P combination studies, mice treated with the combination of radiation and SS1P had a statistically significant prolongation in time to tumor doubling or tripling compared with control, SS1P, or radiation alone. A similar increase in time to tumor doubling or tripling was seen in mice treated with high-dose radiation and SS1P combination. Conclusions: Combination of SS1P with tumor-directed radiation results in enhanced antitumor activity against mesothelin-expressing tumor xenografts. This effect was seen when either low or high doses of radiation were used.


Radiation Oncology | 2009

High throughput evaluation of gamma-H2AX

Dane Avondoglio; Tamalee Scott; Whoon Jong Kil; Mary Sproull; Philip J. Tofilon; Kevin Camphausen

The DNA double-strand break (DSB) is the primary lethal lesion after therapeutic radiation. Thus, the development of assays to detect and to quantitate these lesions could have broad preclinical and clinical impact. Phosphorylation of histone H2AX to form γ-H2AX is a known marker for irradiation-induced DNA DSBs. However, the first generation assay involves the use of immunofluorescent staining of γ-H2AX foci. This assay is time consuming, operator dependent and is not scalable for high throughput assay development. Thus, we sought to develop a new assay using a high throughput electrochemiluminescent platform from Mesoscale Discovery Systems to quantify γ-H2AX levels. The results show that our assay utilizes significantly less time and labor, has greater intra-assay reproducibility and has a greater dynamic range of γ-H2AX versus irradiation dose.


Journal of Cellular and Molecular Medicine | 2007

Post‐collection,pre‐measurement variables affecting VEGF levels in urine biospecimens

Robert M. Hayward; Melissa Kirk; Mary Sproull; Tamalee Scott; Sharon M. Smith; Theresa Cooley-Zgela; Nancy Sears Crouse; Deborah Citrin; Kevin Camphausen

Angiogenesis, the development and recruitment of new blood vessels, plays an important role in tumour growth and metastasis.Vascular endothelial growth factor (VEGF) is an important stimulator of angiogenesis.Circulating and urinary VEGF levels have been suggested as clinically useful predictors of tumour behaviour, and investigations into these associations are ongoing.Despite recent interest in measuring VEGF levels in patients, little is known about the factors that influence VEGF levels in biospecimens. To begin to address this question, urine samples were collected from patients with solid tumours undergoing radiotherapy and healthy volunteers.Four factors were examined for their effects on VEGF concentrations as measured by chemiluminescent immunoassay: time from sample collection to freezing, number of specimen freeze–thaw cycles, specimen storage tube type and the inclusion or exclusion of urinary sediment. The results of this study indicate that time to freeze up to 4 hrs, number of freeze–thaw cycles between one and five, and different types of polypropylene tubes did not have statistically significant effects on measured urinary VEGF levels. Urinary sediment had higher VEGF levels than supernatant in five of six samples from healthy patients.It is not clear whether there is an active agent in the sediment causing this increase or if the sediment particles themselves are affecting the accuracy of the assay.Therefore, we recommend centrifuging urine, isolating the supernatant, and freezing the sample in polypropylene microcentrifuge tubes or cryogenic vials within 4 hrs of collection.In addition, we recommend the use of samples within five freeze–thaw cycles.


Journal of Cellular and Molecular Medicine | 2008

Non-patient related variables affecting levels of vascular endothelial growth factor in urine biospecimens

Melissa Kirk; Robert M. Hayward; Mary Sproull; Tamalee Scott; Sharon M. Smith; Theresa Cooley-Zgela; Nancy Sears Crouse; Deborah Citrin; Kevin Camphausen

Vascular endothelial growth factor (VEGF) is an angiogenic protein proposed to be an important biomarker for the prediction of tumour growth and disease progression. Recent studies suggest that VEGF measurements in biospecimens, including urine, may have predictive value across a range of cancers. However, the reproducibility and reliability of urinary VEGF measurements have not been determined. We collected urine samples from patients receiving radiation treatment for glioblastoma multiforme (GBM) and examined the effects of five variables on measured VEGF levels using an ELISA assay. To quantify the factors affecting the precision of the assay, two variables were examined: the variation between ELISA kits with different lot numbers and the variation between different technicians. Three variables were tested for their effects on measured VEGF concentration: the time the specimen spent at room temperature prior to assay, the addition of protease inhibitors prior to specimen storage and the alteration of urinary pH. This study found that VEGF levels were consistent across three different ELISA kit lot numbers. However, significant variation was observed between results obtained by different technicians. VEGF concentrations were dependent on time at room temperature before measurement, with higher values observed 3–7 hrs after removal from the freezer. No significant difference was observed in VEGF levels with the addition of protease inhibitors, and alteration of urinary pH did not significantly affect VEGF measurements. In conclusion, this determination of the conditions necessary to reliably measure urinary VEGF levels will be useful for future studies related to protein biomarkers and disease progression.


Neuro-oncology | 2014

RT-18TARGETING MPS1 ENHANCES RADIOSENSITIZATION OF HUMAN GLIOBLASTOMA BY MODULATING DNA REPAIR PROTEINS

Uday Bhanu Maachani; Tamalee Scott; Ryan Hanson; Shuping Zhao; Orieta Celiku; Uma Shankavaram; Natasha J. Caplen; Kevin Camphausen; Anita Tandle

During the cell cycle, genomic stability requires accurate chromosome segregation. Errors in this process can cause aneuploidy, leading to tumorigenesis. To ensure faithful chromosome segregation, cells use the spindle assembly checkpoint (SAC) mechanism. However, in aneuploid cancer cells components of the SAC machinery are frequently altered. Thus, targeting the components of SAC machinery required for the growth of aneuploid cells may thus offer a cancer cell specific therapeutic approach. Monopolar spindle 1 (MPS1) is an essential SAC kinase involved in determining spindle integrity. MPS1 is overexpressed in a wide range of tumors and is required for tumor cell proliferation; there is thus increased interest in targeting MPS1 for cancer treatment. In this study, we have analyzed the mechanistic basis of the effects of inhibiting MPS1 in glioblastoma multiforme (GBM). We show that the inhibition of MPS1 in conjunction with radiation reduces GBM cell growth, and clonogenic survival and that this is associated with mitotic cell arrest and induction of mitotic catastrophe. MNS-P715 not alone, but along with fractionated doses of radiation significantly enhanced the tumor growth delay. Using gene expression profiling of GBM cells in which MPS1 was silenced we identified altered expression of genes associated with DNA damage, DNA repair, and DNA replication, including PRKDC, the DNA-dependent protein kinase (DNAPK). Inhibition of MPS1 blocked two important DNA repair pathways, non-homologous end joining and homologous recombination. To our knowledge, this is the first report demonstrating a role for MPS1 in DNA repair. Data mining of publically available databases showed the clinical relevance of MPS1 as an important cancer target in GBM. We conclude that inhibiting MPS1 kinase in combination with DNA damage, including irradiation, could represent a promising new approach to cancer therapy.

Collaboration


Dive into the Tamalee Scott's collaboration.

Top Co-Authors

Avatar

Kevin Camphausen

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Mary Sproull

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Philip J. Tofilon

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Deborah Citrin

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Anita Tandle

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

C. Norman Coleman

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Cynthia Ménard

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Dennis F. Deen

University of California

View shared research outputs
Top Co-Authors

Avatar

Martin W. Brechbiel

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Melissa Kirk

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge